| (USD) | Jun 2023 | Q/Q |
|---|---|---|
| Revenue | 1.8MM | -5% |
| Operating Income | -20.4MM | -11% |
| Operating Expenses | 22.2MM | - |
| Net Income | -20.3MM | -11% |
| Amortization | 1.2MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has teamed up with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to launch the first RRP Awareness Day™ on June 11, 2024, a multi-stakeholder event to raise awareness about recurrent respiratory papillomatosis (RRP) and bring together RRP patients and their caregivers to encourage new conne
Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript March 19, 2024 Precigen, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $-0.08. PGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the […]
Challenges Persist as Total Revenues Decline by 76.9% Year-Over-Year
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2023 financial results and business updates.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Cantor Fitzgerald will be hosting a virtual fireside chat with Precigen on Monday, March 25, 2024 at 1:00 PM ET to discuss the investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP). The event will be hosted by Jennifer Kim, Biotechnology Analyst at Canto
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.
With the business potentially at an important milestone, we thought we'd take a closer look at Precigen, Inc.'s...
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024. Precigen's company presentation will take place on Tuesday, February 13 from 3:20 PM to 3:50 PM EST.
Quite a few insiders have dramatically grown their holdings in Precigen, Inc. ( NASDAQ:PGEN ) over the past 12 months...
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the European Commission (EC) has granted Orphan Drug Designation for the Company's first-in-class investigational medicine PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP). RRP is a rare, difficult-to-treat and sometimes fatal neoplastic disease of the upper and lower respiratory tracts cau